Table 1.

Patients’ characteristics

Variables
Median age, years (range)	71.2 (52.5–82.9)
Cycles of docetaxel, cycles (range)	9 (1–55)
Use of enzalutamide, n (%)	35 (72.9)
Use of abiraterone acetate, n (%)	26 (54.1)
Median aBSI, %, (range)	3.5 (0.0–12.9)
Median baseline PSA, ng/mL (range)	152.1 (1.6–3564.0)
Median baseline Hb, g/dL (range)	11.0 (8.1–14.2)
Median baseline LDH, IU/L (range)	262 (124–3509)
Median baseline ALP, IU/L (range)	414 (111–3653)
Lymph node metastasis, n (%)	32 (66.6)
Visceral metastasis, n (%)	23 (47.9)
Cycles of cabazitaxel, cycles (range)	4 (1–15)
Median observation period, months (range)	7.2 (0.6–25.0)
Cancer death, n (%)	25 (56.2)

aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen